FuboTV, Q1
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
May 2, 2024 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1. Arbutus Biopharma Corporation isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires.
The Arbutus Club in Vancouver is debunking a rumour that's making rounds about members who had group sex in the parkade.
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024Preliminary ...
WARMINSTER, Pa. — WARMINSTER, Pa. — Arbutus Biopharma Corp. (ABUS) on Thursday reported a loss of $17.9 million in its first quarter. The Warminster, Pennsylvania-based company said it had a loss of ...
If finding Trailing Arbutus blooms proves difficult due to cover from vegetation, don’t be afraid to follow your nose, writes ...
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago. These figures are adjusted ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arbutus Biopharma (ABUS – Research Report), ...
The simple layout of this home is one of its main assets, as it allows for a seamless transition between functional spaces ...
Arbutus Biopharma Corp (NASDAQ:ABUS) has initiated patient screening in their third Phase 2a clinical trial, AB-729-203, evaluating induceran in combination with durvalumab, an anti-PD-L1 monoclonal ...
Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 First Quarter Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen ...
Arbutus Biopharma Corporation (Nasdaq: ABUS) has unveiled its growth during the first quarter of 2024, particularly in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback